The 22nd China International In Vitro Diagnostics Expo by CACLP and the 5th China IVD Supply Chain Expo (CISCE) took place from 22–24 March 2025 in Hangzhou, achieving unprecedented scale and impact. CACLP 2025 attracted a record-breaking 45,071 professional visitors, marking a 5.4% increase over the previous year. Notably, international attendance more than doubled, with visitors from over 60 countries and regions, reaffirming CACLP’s growing global influence and strategic importance within the in vitro diagnostic (IVD) industry.
Spanning 130,000 square meters across seven major halls, the event hosted 1,350 exhibitors from 23 countries and regions, making it one of the most internationally diverse editions to date. The exhibition featured eight specialized zones—Instruments & Reagents, Raw Materials, Consumables, Components, General Laboratory Equipment, Supply Chain Solutions, the International Pavilion, and the newly launched Veterinary Diagnosis Pavilion—delivering comprehensive coverage of the entire IVD chain while highlighting emerging frontiers.
The enhanced exhibition layout further promoted global exchange, spotlighting exhibitor groups from Canada and Germany, and active participation from industry players across India, South Korea, Switzerland, the U.K., the U.S., and Vietnam. For the first time, government agencies, regulatory authorities, medical associations, and companies hosted roadshows in upgraded Presentation Areas. These 10- and 20-minute presentations provoked in-depth dialogues on diverse industry trends and market access and attracted strong attention from professional participants.
To amplify its global reach, CACLP 2025 leveraged digital platforms, livestreaming expo tours, conference sessions, and product showcases. With its highest-ever turnout, expanded global participation, and increasingly diverse programming, CACLP 2025 firmly cemented its reputation as one of the world’s largest and most influential IVD events, all while underscoring China’s vital role in the global diagnostics ecosystem.
Scenes from CACLP 2025
Another major highlight was the robust lineup of over 300 academic and business activities from 21-23 March, including the 10th China Experimental Medicine Conference (CEMC) and series sessions, welcomed leading academicians, hospital presidents, and biomedical experts to discuss advancements in AI-driven diagnostics, laboratory quality management and personalized treatment. The 12th China IVD Industry Development Conference (CIIDC) provided key insights into sustainability, emerging tech, investment strategies, and global healthcare developments, while also officially presenting the Annual Report of China IVD Industry 2024, which delivered authoritative market analysis and trend forecasts.
Other key industry events included Enlightening Lab Med – The 8th IVD Youth Entrepreneur Forum (ELMY), the 7th China IVD Distribution Enterprise Forum (CIDEF), and the 5th China Key Raw Material & Parts Forum (CKRMPF), covering topics such as entrepreneurial innovation, distribution trends, and advancements in raw material standardization and quality.
In addition to its well-established conferences and forums, CACLP 2025 introduced four highly anticipated sessions addressing key transformations in the industry. The 1st AI & Digital Twin Technology Academic Salon provided insights into the integration of AI in diagnostics, accelerating the shift toward intelligent and precision-driven healthcare. The 1st Human-to-Animal Medical Device Transition Forum, co-hosted with the East and West Small Animal Veterinary Conference, explored how human diagnostic innovations are shaping the veterinary market. The 1st National Primary Healthcare Laboratory Forum focused on quality control, test standardization, and expanding access to advanced diagnostics in grassroots laboratories. Meanwhile, the 1st China IVD Companies Globalization Forum provided essential guidance on international regulatory pathways and expansion strategies.
Snapshots from CACLP 2025’s Academic and Business Activities
CACLP 2026 will return in March 2026. For more information, visit en.caclp.com.
About GL events
GL events is a world-class leading provider of integrated solutions and services for events operating across the 3 major core divisions: Venues (venue management), Exhibitions (exhibition organizing) and Live (event services).
Through its wide global network made up of more than 90 offices, with organizing over 480 proprietary trade fair and events, managing more than 60 venues, and staging more than 4,200 events every year, GL events Group is a critical force for city promotion of 28 MICE destinations.
Present on five continents with operations in more than 20 countries, GL events has over 5,119 employees. Listed on the Eurolist Euronext Compartment B (Paris Stock Exchange), GL events had a turnover of �1.315bn in 2022.
About CACLP
Debut launched in 1991, China International In Vitro Diagnostic Expo by CACLP, is well established as one of the largest exhibitions in the in vitro diagnostic industry worldwide. China IVD Supply Chain Expo, successfully launched in 2021, further expands the product sectors from upstream to downstream. With a great number of high-level academic and educational programs held concurrently onsite, and year-round promotional solutions, CACLP proves itself as one of the most important platforms for global IVD players.
In 2020, CACLP formed the joint-venture company with GL events to start the internationalism strategy.
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.